Aaron Gerlach works to grow Icagen’s business from a scientific perspective, including the development of scientific plans and project leadership for collaborators. Dr. Gerlach previously led multiple ion channel-focused projects at Icagen and within Pfizer, including the development of KCNQ small molecules for the treatment of drug-resistant epilepsy.